Jermaine D Jones

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9324607/publications.pdf

Version: 2024-02-01

59	2,045	304743	243625
papers	citations	22 h-index	44 g-index

59	59	59	2552
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Emotional Reactions of Trained Overdose Responders who use Opioids following Intervention in an Overdose Event. Substance Abuse, 2022, 43, 581-591.	2.3	2
2	The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamineâ€™s effects. Behavioural Pharmacology, 2022, Publish Ahead of Print, .	1.7	2
3	A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder. Drug and Alcohol Dependence, 2022, 237, 109505.	3.2	5
4	A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.. International Journal of Drug Policy, 2021, 87, 102968.	3.3	5
5	The Increasing Prevalence of Fentanyl: A Urinalysisâ€Based Study Among Individuals With Opioid Use Disorder in New York City. American Journal on Addictions, 2021, 30, 65-71.	1.4	26
6	Factor structure and psychometric properties of the Connorâ€“Davidson resilience scale (CD-RISC) in individuals with opioid use disorder. Drug and Alcohol Dependence, 2021, 221, 108632.	3.2	11
7	Relative potency of intravenous oxymorphone compared to other Âµ opioid agonists in humans â€” pilot study outcomes. Psychopharmacology, 2021, 238, 2503-2514.	3.1	4
8	Multi-informant Implementation and Intervention Outcomes of Opioid Overdose Education and Naloxone Distribution in New York City. Global Implementation Research and Applications, 2021, 1, 209-222.	1.1	1
9	Improving Translational Research Outcomes for Opioid Use Disorder Treatments. Current Addiction Reports, 2021, 8, 109-121.	3.4	9
10	A randomized, doubleâ€blind, placeboâ€controlled study of the kappa opioid receptor antagonist, CERCâ€501, in a human laboratory model of smoking behavior. Addiction Biology, 2020, 25, e12799.	2.6	15
11	Naloxoneâ€Induced Withdrawal in Individuals With and Without Fentanylâ€Positive Urine Samples. American Journal on Addictions, 2020, 29, 51-56.	1.4	2
12	Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder. Substance Abuse, 2020, 42, 1-5.	2.3	8
13	The acute and repeated effects of cigarette smoking and smokingâ€related cues on impulsivity. Drug and Alcohol Review, 2020, 40, 864-868.	2.1	2
14	Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: Exploratory mixed methods analysis. Journal of Substance Abuse Treatment, 2020, 117, 108099.	2.8	10
15	Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder. Drug and Alcohol Dependence, 2020, 208, 107859.	3.2	24
16	Potential of Glial Cell Modulators in the Management of Substance Use Disorders. CNS Drugs, 2020, 34, 697-722.	5.9	9
17	Opioid overdose reversals using naloxone in New York City by people who use opioids: Implications for public health and overdose harm reduction approaches from a qualitative study. International Journal of Drug Policy, 2020, 79, 102751.	3.3	15
18	Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone. Pharmacology Biochemistry and Behavior, 2019, 186, 172778.	2.9	9

#	Article	IF	Citations
19	How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies. Addiction, 2019, 114, 708-718.	3.3	38
20	Changes in cardiac vagal tone as measured by heart rate variability during naloxone-induced opioid withdrawal. Drug and Alcohol Dependence, 2019, 204, 107538.	3.2	6
21	The PPARÎ³ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. Journal of Psychoactive Drugs, 2018, 50, 390-401.	1.7	15
22	Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology, 2017, 42, 1825-1832.	5.4	59
23	No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone. Addictive Behaviors, 2017, 71, 104-106.	3.0	49
24	Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder. Journal of Psychoactive Drugs, 2017, 49, 59-68.	1.7	6
25	Pioglitazone, a PPARÎ³ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. Pharmacology Biochemistry and Behavior, 2017, 163, 90-100.	2.9	24
26	Glial and neuroinflammatory targets for treating substance use disorders. Drug and Alcohol Dependence, 2017, 180, 156-170.	3.2	79
27	Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount. Drug and Alcohol Dependence, 2017, 179, 362-369.	3.2	15
28	Chronic pain and opioid abuse: Factors associated with healthâ€related quality of life. American Journal on Addictions, 2017, 26, 815-821.	1.4	21
29	Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder. JAMA Psychiatry, 2017, 74, 894.	11.0	58
30	Can Naloxone Be Used to Treat Synthetic Cannabinoid Overdose?. Biological Psychiatry, 2017, 81, e51-e52.	1.3	10
31	The effects of heroin administration and drug cues on impulsivity. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 709-720.	1.3	16
32	Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms. American Journal on Addictions, 2016, 25, 41-48.	1.4	17
33	The effects of pioglitazone, a PPARÎ³ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users. Physiology and Behavior, 2016, 159, 33-39.	2.1	18
34	The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addiction Biology, 2016, 21, 895-903.	2.6	85
35	Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphineâ€maintained heroin users. Addiction Biology, 2015, 20, 784-798.	2.6	28
36	The Pharmacogenetics of Alcohol Use Disorder. Alcoholism: Clinical and Experimental Research, 2015, 39, 391-402.	2.4	71

#	Article	IF	Citations
37	A review of pharmacogenetic studies of substance-related disorders. Drug and Alcohol Dependence, 2015, 152, 1-14.	3.2	29
38	Sex Differences Among Opioid-Abusing Patients With Chronic Pain in a Clinical Trial. Journal of Addiction Medicine, 2015, 9, 46-52.	2.6	46
39	Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users. Drug and Alcohol Dependence, 2015, 153, 201-206.	3.2	10
40	Brief overdose education can significantly increase accurate recognition of opioid overdose among heroin users. International Journal of Drug Policy, 2014, 25, 166-170.	3.3	46
41	The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users. Pharmacology Biochemistry and Behavior, 2014, 122, 299-306.	2.9	11
42	A comparison among tapentadol tamperâ€resistant formulations (<scp>TRF</scp>) and <scp>O</scp>xy<scp>C</scp>ontin^{Â®} (nonâ€<scp>TRF</scp>) in prescription opioid abusers. Addiction, 2013, 108, 1095-1106.	3.3	38
43	Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol Use. Postgraduate Medicine, 2013, 125, 115-130.	2.0	179
44	Effects of Acute Oral Naltrexone on the Subjective and Physiological Effects of Oral D-Amphetamine and Smoked Cocaine in Cocaine Abusers. Neuropsychopharmacology, 2013, 38, 2427-2438.	5.4	49
45	Opioid-Like Effects of the Neurokinin 1 Antagonist Aprepitant in Patients Maintained on and Briefly Withdrawn from Methadone. American Journal of Drug and Alcohol Abuse, 2013, 39, 86-91.	2.1	13
46	A review of human drug self-administration procedures. Behavioural Pharmacology, 2013, 24, 384-395.	1.7	44
47	Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts. Behavioural Pharmacology, 2013, 24, 504-516.	1.7	25
48	Glial modulators: a novel pharmacological approach to altering the behavioral effects of abused substances. Expert Opinion on Investigational Drugs, 2012, 21, 169-178.	4.1	42
49	Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug and Alcohol Dependence, 2012, 125, 8-18.	3.2	565
50	Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug and Alcohol Dependence, 2012, 126, 206-215.	3.2	42
51	Impact of inâ€patient research participation on subsequent heroin use patterns: implications for ethics and public health. Addiction, 2012, 107, 642-649.	3.3	4
52	Oxycodone Abuse in New York City: Characteristics of Intravenous and Intranasal Users. American Journal on Addictions, 2011, 20, 190-195.	1.4	23
53	The Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Patients with Chronic, Non-Malignant Pain who are Maintained on Sublingual Buprenorphine/Naloxone. Neuropsychopharmacology, 2011, 36, 411-422.	5.4	25
54	Dopamine, norepinephrine and serotonin transporter gene deletions differentially alter cocaine-induced taste aversion. Pharmacology Biochemistry and Behavior, 2010, 94, 580-587.	2.9	22

#	Article	IF	Citations
55	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacology Biochemistry and Behavior, 2009, 93, 75-81.	2.9	22
56	Strain-dependent sex differences in the effects of alcohol on cocaine-induced taste aversions. Pharmacology Biochemistry and Behavior, 2006, 83, 554-560.	2.9	20
57	Behavioral effects and drug vulnerability in rats exposed to Pfiesteria toxin. Neurotoxicology and Teratology, 2005, 27, 701-710.	2.4	5
58	The effects of cocaine, alcohol and cocaine/alcohol combinations in conditioned taste aversion learning. Pharmacology Biochemistry and Behavior, 2005, 82, 207-214.	2.9	11
59	Understanding preferences for type of take-home naloxone device: international qualitative analysis of the views of people who use opioids. Drugs: Education, Prevention and Policy, 0, , 1-12.	1.3	0